Dienogest 2 mg Daily in the Treatment of Adolescents with Clinically Suspected Endometriosis: The VISanne Study to Assess Safety in ADOlescents.

Study Objective: To study the safety and efficacy of dienogest 2 mg in adolescents with suspected endometriosis.

Design: A 52-week, open-label, single-arm study.

Setting: In 21 study centers, in 6 European countries.